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Abstract
Background: Opiate addiction reflects plastic changes that endurably alter synaptic transmission
within relevant neuronal circuits. The biochemical mechanisms of these adaptations remain largely
unknown and proteomics-based approaches could lead to a broad characterization of the
molecular events underlying adaptations to chronic drug exposure.
Results: Thus, we have started proteomic analyses of the effects of chronic morphine exposure
in a recombinant human neuroblastoma SH-SY5Y clone that stably overexpresses the μ-opioid
receptor. Cells were treated with morphine for 6, 24 and 72 hours, the proteins were separated
by 2-D gel electrophoresis and stained with Coomassie blue, and the protein map was compared
with that obtained from untreated cells. Spots showing a statistically significant variation were
selected for identification using mass spectrometric analyses.
Conclusion:  A total of 45 proteins were identified, including proteins involved in cellular
metabolism, cytoskeleton organization, vesicular trafficking, transcriptional and translational
regulation, and cell signaling.
Background
Opiate addiction, a pathological form of learning and
memory associated with repeated drug use or administra-
tion, reflects neuronal adaptive/plastic changes that
endurably alter synaptic transmission within relevant cir-
cuits in the central nervous system [1-4]. The biochemical
mechanisms underlying the functional and structural
adaptations to chronic opiate exposure remain largely
unknown. Elucidating them in details is important, as this
is expected to reveal novel pharmacological strategies for
preventing formation and/or expression of dependence,
with potential benefits for the treatment of chronic pain
and addiction.
The biochemical mechanisms of drug dependence have
begun to be examined globally by using DNA microarray-
and/or proteomics-based approaches. Thus, DNA micro-
array-based approaches have been used in order to study
gene expression induced by drugs of abuse [5], including
opiates [6,7], but interpretation of the results is limited –
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mRNA levels do not necessarily reflect proteins levels [8]
– and no information about post-transcriptionally modi-
fied proteins is provided. In principle, proteomics-based
approaches could lead to a much broader characterization
of the molecular events underlying drug dependence. Yet,
the successful application of differential proteomics to
identify drug-induced protein changes in the central nerv-
ous system represent a technical challenge because of its
cellular heterogeneity [9].
Obviously, sample heterogeneity is much less of a prob-
lem in cultured clonal cell lines than in nerve tissue. Thus,
we have started proteomic analyses of the effects of
chronic morphine exposure in a recombinant human
neuroblastoma SH-SY5Y clone that stably overexpresses
the μ-opioid (MOP) receptor. Wild-type SH-SY5Y cells
express low levels of MOP receptor, and even lower (3- to
4-fold) levels of delta opioid (DOP) receptor [10], and are
only poorly responsive to both acute and long-term mor-
phine treatment [11]. In marked contrast, in MOP recep-
tor-overexpressing cells, acute morphine is much more
potent and efficacious in inhibiting forskolin-elicited pro-
duction of cAMP, and chronic morphine induces a higher
degree of adenylate cyclase sensitization, a hallmark of
opiate dependence, than in the parent (wild type) cells
[11]. The dramatically increased responsiveness of MOP-
overexpressing over wild-type cells is an indication that
the observed effects are MOP receptor- rather than DOP
receptor-mediated. The cells were treated with morphine
for 6, 24 and 72 hours, the proteins were separated by 2-
D electrophoresis (2-DE) and stained with colloidal
Coomassie blue, and the protein map was compared with
that obtained from untreated cells. Spots showing a statis-
tically significant variation were selected for identification
using a combination of MALDI-TOF MS (matrix-assisted
laser desorption/ionization time of flight mass spectrom-
etry) and nanoLC-ESI-Q-TOF MS/MS (liquid-chromatog-
raphy electrospray ionization quadrupole time of flight)
analyses. A total of 45 proteins were found to have varied
in abundance in the course of long-term exposure to mor-
phine, including proteins involved in cellular metabo-
lism, cytoskeleton organization, vesicular trafficking,
transcriptional and translational regulation, and cell sign-
aling.
Results
Figure 1 shows a representative bi-dimensional map of
the proteome of untreated (control) neuroblastoma SH-
SY5Y cells. Colloidal Coomassie blue protein staining,
followed by automatic feature detection and manual edit-
ing enabled visualization of about 950 individual spots
on a 2-D gel.
The protein map of neuroblastoma cells having been
treated with 1 μM morphine for 6 hours was compared
with that of untreated cells. A 6 h treatment with mor-
phine was selected since such treatment was previously
shown to elicit nearly maximum sensitization of ade-
nylate cyclase, an index of opiate dependence, in these
cells [11]. As shown on Figure 1, the protein pattern from
6 h-treated cells was globally very similar to that of control
cells. After image analysis, the abundance of each spot was
estimated relative to the abundance of all spots in the gel
(see Methods). Four control gels were matched with four
6 h morphine-treatment gels and the spots showing a sta-
tistically significant variation in relative abundance (Stu-
dent t test, p < 0.05) were selected for identification by
mass spectrometry. Eighteen spots displayed such signifi-
cant variation: 11 spots were upregulated by a factor 1.22
to 2.03 following morphine treatment, while 7 spots were
downregulated by a factor 0.35 to 0.75. These spots were
cut from a gel, digested by trypsin and analyzed by pep-
tide mass fingerprinting using MALDI-TOF mass spec-
trometry. When peptide mass fingerprinting data was not
sufficient for confident identification, trypsin digests were
also analyzed using nanoLC-ESI-MS/MS. The combina-
tion of these two methods enabled the unambiguous
identification of 18 proteins whose name, accession
number, change in relative abundance and MS data are
summarized on Table 1. Spot numbers in this table refer
to the ones in Figure 2, which depicts the location of every
spot that was identified in this study on a representative 2-
D gel. Spot 11 could not be identified while spot 24 con-
tained a mixture of 2 proteins.
We next examined the proteome effects of exposing the
neuroblastoma cells to morphine (1 μM) for longer peri-
ods of time, i.e. 24 and 72 hours. Twenty one spots were
found to display a significant variation in relative abun-
dance after a 24 h morphine treatment: 11 spots were
upregulated by a factor 1.18 to 1.84, whilst 10 spots were
downregulated by a factor 0.45 to 0.84. Among these, 18
spots could be attributed to one protein, and 3 spots con-
tained a mixture of 2 proteins (Table 2). 2 spots with sim-
ilar molecular weights but different pIs contained the
same protein (α-enolase). The relative volume of these 2
spots varied in opposite direction after morphine treat-
ment suggesting a change in post-translational modifica-
tion, possibly phosphorylation. Twenty-five spots
displayed a significant variation in relative abundance
after a 72 h morphine treatment: 5 spots were upregulated
by a factor 1.1 to 1.79, whilst 20 spots were downregu-
lated by a factor of 0.45 to 0.84. Among these, 21 could be
attributed to one protein, 2 contained a mixture of 2 pro-
teins, and 2 could not be identified (Table 3).
The pattern of morphine-responsive proteins was clearly
dependent upon the duration of exposure of the cells to
morphine. In fact, only 8 proteins were found to be signif-
icantly regulated at 2 or 3 time points. Vacuolar ATP syn-Proteome Science 2006, 4:23 http://www.proteomesci.com/content/4/1/23
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thase subunit B and bifunctional purine biosynthesis
protein were upregulated at 6 and 24 h. Rab7 was down-
regulated at 6 and 24 h while guanine nucleotide binding
protein β subunit 2-like 1 (also known as RACK1) was
downregulated at 6 and 72 h. Adenylosuccinate syn-
thetase 2 was upregulated at 6 h and downregulated at 72
h. Septin 11 and spot 24 containing a mixture of Rab GDI
β and mitochondrial-processing peptidase β were upregu-
lated at 6 h, returned to baseline at 24 h and showed only
a minor upregulation at 72 h. Finally, only malate dehy-
drogenase was downregulated at each time point.
Discussion
Overall, the present whole cell proteomic analysis has
identified 53 proteins from 55 spots whose relative vol-
ume is modified upon morphine treatment in SH-SY5Y
cells. Once mixtures are excluded, 45 morphine-respon-
sive proteins can be classified according to cellular func-
tion (see Additional file 1). These are involved in cell
metabolism, organization of the cytoskeleton, vesicle traf-
ficking, transcriptional regulation, protein translation,
folding and degradation, and cell signaling.
The pattern of morphine-responsive proteins appears to
be dependent on the duration of morphine treatment
(compare Tables 1, 2 and 3), indicating that cellular adap-
tation to chronic morphine is a dynamic process. Such
dynamic adaptation has previously been documented in
the striatum of chronically morphine-treated rats,
wherein various members of the Fos family of transcrip-
tion factors are sequentially upregulated, implying that
distinct sets of genes are regulated over time [3]. Alterna-
tively, it is possible that changes could have been missed
at some time point due to technical limitation. For exam-
ple, RACK1 was found to be downregulated at each time
point but this downregulation reached statistical signifi-
cance only for the 6 and 72 h time points. The difficulty to
detect subtle variations in low abundance proteins is a
well known limitation of large scale proteomic studies.
Thus, the present whole cell analysis failed to detect
2-DE pattern of untreated (A) and 6 h morphine-treated (B) SH-SY5Y cells Figure 1
2-DE pattern of untreated (A) and 6 h morphine-treated (B) SH-SY5Y cells. Sample were resolved by 2-DE on non-
linear pH 3–10 IPG strips followed by separation on a 12% SDS-PAGE gel in the second dimension. Proteins were visualized by 
colloidal coomassie staining. The box in 1B delineates the close-up presented on figure 2.Proteome Science 2006, 4:23 http://www.proteomesci.com/content/4/1/23
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changes in heterotrimeric G protein β subunits and pro-
hibitin whose relative abundance was previously shown
to be decreased in the detergent-resistant membrane
(DRM) raft fraction isolated from morphine-treated cells
[11]. This is readily explained by the fact that standard
sample preparation for 2-DE (the present study), which
involves incubation with Triton X-100 at 4°C followed by
high speed centrifugation, has eliminated the DRM raft
fraction and the proteins which this fraction is enriched
in, including heterotrimeric G protein subunits [11]. In
addition, the present study has focused onto the ~950
most abundant and soluble proteins of the cell, which
represent only 1 to 10% of the total protein species likely
to be expressed in a cell. This illustrates the necessity of
combining both whole cell and sub-proteome targeted
analyses to obtain a clear picture of the proteome of a
given cell type.
Four recently published proteomic analyzes have
addressed chronic morphine effects in the brain [12-15].
Seven of our morphine-responsive proteins, or closely
related isoforms, were also found to be modified in these
studies: ATP synthase beta chain, vacuolar ATP synthase
subunit B, malate dehydrogenase, triosephosphate iso-
merase, rab GDP dissociation inhibitor beta, peptidyl-
prolyl isomerase, and septin-11. These are indications that
at least some of the brain protein changes associated with
chronic morphine treatment in vivo can be reproduced in
our cellular model in vitro after a relatively short time of
morphine exposure. Conversely, some of the new changes
identified in our present in vitro study may provide hints
as to what neuronal processes may be regulated upon
chronic morphine treatment in vivo.
Ascribing a precise role for the identified proteins in medi-
ating specific chronic morphine effects in neurons would
be too speculative at this stage. However it appears note-
worthy to highlight possible links between selected pro-
teins identified in this study and known effects of chronic
morphine. Similar to what was recently described for
cocaine [16], some of morphine transcriptional effects
could be mediated at the level of histone acetylation and
chromatin remodeling since two histone acetyltransferase
subunits (RuvB-like 1 and histone acetyltransferase type B
subunit 2) are upregulated after 24 h of treatment. The
variation in 20S proteasome subunit composition
observed after 72 h of morphine is consistent with previ-
ous studies demonstrating a role for the ubiquitin/protea-
some pathway in mediating chronic morphine effects
[11,17].
Such transcriptional and post-translational regulations
can lead to numerous changes in cellular function among
which alterations in cellular architecture [18,19], vesicle
trafficking [4] and signal transduction pathways are essen-
tial for drug-induced neuronal plasticity. Regarding neu-
ronal architecture and synaptic remodelling, potentially
interesting morphine targets are ERM proteins, septins
Table 1: Proteins whose abundance in SH-SY5Y cells is regulated after 6 h of morphine treatment
Spot # Protein Accession # (a) MW (Da) Variation (% of 
control) (b)
MALDI peptides % coverage MS/MS peptides (c)
2 Elongation factor G 1 Q96RP9 83506 42 ± 11 13 16
3 Ezrin P15311 69268 165 ± 26 10 15
5 Lamin A/C P02545 74139 203 ± 21 18 32
9 Bifunctional purine biosynthesis protein P31939 65088 122 ± 16 14 30
11 no identification 52 ± 10
14 Vacuolar ATP synthase subunit B, brain 
isoform
P21281 56501 151 ± 17 18 54
15 Rho-GTPase-activating protein 1 Q07960 50461 166 ± 44 4
17 Septin-11 Q9NVA2 49267 141 ± 19 13 37
18 ATP synthase beta chain P06576 56560 35 ± 9 10 48
24 Rab GDP dissociation inhibitor beta
Mitochondrial-processing peptidase beta 
subunit
P50395
O75439
50663
55072
136 ± 16 14
12
36
25
27 Synaptic vesicle membrane protein VAT-1 
homolog
Q99536 41920 141 ± 17 7 31
28 Adenylosuccinate synthetase 2 P30520 50097 147 ± 14 5
36 40 kDa peptidyl-prolyl cis-trans isomerase Q08752 40632 174 ± 42 12 26
44 Malate dehydrogenase, cytoplasmic P40925 36295 50 ± 9 11 32
49 Guanine nucleotide binding protein beta 
subunit 2-like 1
P63244 35077 75 ± 15 15 69
52 Platelet-activating factor acetylhydrolase IB 
gamma
Q15102 25734 70 ± 14 5
53 Triosephosphate isomerase P60174 26538 186 ± 60 13 65
54 Ras-related protein Rab-7 P51149 23490 56 ± 13 13 65
aSwiss-Prot primary accession number
bMean ± S.D., control refers to untreated cells.
cOnly peptides with a statistically significant Mascot score (p < 0.05) were consideredProteome Science 2006, 4:23 http://www.proteomesci.com/content/4/1/23
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[20] and Rho-GTPase-activating protein 1 [21]. Concern-
ing vesicular transport, the SNAP-alpha downregulation
observed in our study is consistent with the recent obser-
vation that chronic morphine could induce an inhibition
of SNARE complex formation [22]. Morphine could also
act at the level of small GTPases of the rab family which
are essential for vesicle trafficking. The observed increase
in rab GDP dissociation inhibitor beta after 72 h of mor-
phine could result in an alteration of the amount of active
rab proteins available for neurotransmitter release [23].
These data are all consistent with chronic morphine mod-
ifying neurotransmitter secretion and synapse efficacy.
Close-up from a representative 2-D gel showing the spots whose abundance in SH-SY5Y cells is regulated after chronic mor- phine treatment Figure 2
Close-up from a representative 2-D gel showing the spots whose abundance in SH-SY5Y cells is regulated after 
chronic morphine treatment. Spots numbers refer to numbers on Tables 1, 2 and 3 where quantitative analysis and mass 
spectrometric data are presented.Proteome Science 2006, 4:23 http://www.proteomesci.com/content/4/1/23
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Finally, chronic morphine induced a change in abun-
dance of several signaling proteins: heterotrimeric G pro-
tein subunit α i2, serine-threonine kinase receptor
associated protein and receptor for activated C kinase 1
(RACK1). The downregulation of Gα i2 has already been
described in our previous study [11] and will not be dis-
cussed further. The observed upregulation of serine-threo-
nine kinase receptor associated protein provides a new
link between morphine signaling and the phosphatidyli-
nositol 3-kinase/Akt pathway [24]. RACK1 downregula-
tion in brains of morphine-treated rats has been described
previously but it has only been discussed in terms of
changes in PKC activity since it was its only known func-
tion at this time [25]. Since then, RACK1 has been charac-
terized as a scaffolding protein for many proteins involved
in cell signaling [26]. Alterations in RACK1 abundance
could thus coordinate changes in distinct signaling path-
ways and its role in molecular adaptations to drugs of
abuse deserves further investigation [27].
Conclusion
In conclusion, our differential proteomics study has iden-
tified several candidate proteins that could be implicated
in the molecular adaptation of neurons to chronic mor-
phine treatment. In particular, changes in vesicular traf-
ficking and proteasome-dependent protein degradation
are known to be critical for various forms of synaptic plas-
ticity such as long term potentiation or depression
[28,29]. These adaptations as well as their role in the
development of drug dependence have now to be vali-
dated in animal models of addiction.
Methods
Cell culture and treatment
Human SH-SY5Y neuroblastoma cells were transfected
with N-terminal T7-tagged human MOP receptor in pRC-
CMV using lipofectamine [11]. Stably transfected G418-
resistant cells were grown in high glucose DMEM (Gibco
BRL) containing 10% fetal calf serum, 50 μg/ml gentami-
cine (Gibco BRL), and 400 μg/ml G418 (Gibco BRL), in
5% CO2 at 37°C. Cells in 14 cm dishes were treated by
diluting morphine sulphate directly in the culture
medium. The cell density was adjusted so that the cultures
were nearly confluent at the end of each treatment. For 72
h treatment, medium was changed and fresh morphine
was added every day. Four independent experiments were
performed for each treatment time.
Table 2: Proteins whose abundance in SH-SY5Y cells is regulated after 24 h of morphine treatment
Spot # Protein Accession # (a) MW (Da) Variation (% of 
control) (b)
MALDI peptides % coverage MS/MS peptides (c)
1 ATP-dependent RNA helicase DDX1 Q92499 82432 54 ± 10 27 32
7 Glycerol-3-phosphate dehydrogenase, 
mitochondrial
P43304 80815 75 ± 7 15 22
9 Bifunctional purine biosynthesis protein P31939 65088 118 ± 11 14 30
14 Vacuolar ATP synthase subunit B, brain 
isoform
P21281 56501 131 ± 13 18 54
16 RuvB-like 1 Q9Y265 50228 144 ± 32 16 66
19 4-trimethylaminobutyraldehyde 
dehydrogenase
WD-repeat protein 12
P49189
Q9GZL7
53802
48190
145 ± 24 15
12
32
25
20 Alpha-enolase P06733 47038 45 ± 15 18 60
21 Alpha-enolase P06733 47038 184 ± 53 6
22 Histone acetyltransferase type B subunit 2 Q16576 47820 145 ± 65 10 30
30 Heterogeneous nuclear riboprotein F
Eucaryotic translation initiation factor 3 
subunit 5
O00303
45853
37654
181 ± 60 12
7
42
32
32 Beta-succinyl CoA synthetase Q7Z503 43611 74 ± 10 15 35
33 Galactokinase P51570 42272 58 ± 9 15 43
35 Acyl-CoA hydrolase O00154 41796 166 ± 33 11 44
37 Arsenical pump-driving ATPase O43681 38793 167 ± 29 8 26
38 Serine-threonine kinase receptor 
associated protein
Q9Y3F4 38756 164 ± 31 14 48
41 Protein phosphatase 2A, regulatory subunit 
B'
Calponin-3
Q15257
Q15417
40682
36561
65 ± 8 10
7
30
30
42 Biliverdin reductase A P53004 33428 84 ± 6 12 44
44 Malate dehydrogenase, cytoplasmic P40925 36295 49 ± 25 11 32
46 Annexin A5 P08758 35806 152 ± 41 18 70
51 Endoplasmic reticulum protein ERp29 P30040 28993 76 ± 14 8 46
54 Ras-related protein Rab-7 P51149 23490 58 ± 12 13 65
aSwiss-Prot primary accession number
bMean ± S.D., control refers to untreated cells.
cOnly peptides with a statistically significant Mascot score (p < 0.05) were consideredProteome Science 2006, 4:23 http://www.proteomesci.com/content/4/1/23
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Sample preparation for 2-DE
Following treatment, the culture medium was removed
and the cells were scraped into PBS and centrifuged at
1000 × g for 10 min at 4°C. The supernatant was dis-
carded and the pellet was frozen and stored at -80°C for 2
hours. Cells were then resuspended in 500 μl of lysis
buffer [50 mM Tris-HCl pH 7.4, 150 mM NaCl, 10 mM
EDTA, proteinase inhibitors (Complete Mini tablets,
Roche) and 1% (v:v) Triton X-100 (Sigma)], and protein
extraction allowed to proceed for 3 h at 4°C. The extract
was centrifuged at 20,000 × g for 20 min at 4°C in order
to remove cell debris and insoluble material. The superna-
tant was delipidated and desalted using methanol/chloro-
form precipitation by mixing with 2 ml of methanol, 500
μl of chloroform and 1.5 ml of water, and centrifuging at
20,000 × g for 5 min, at room temperature. The pellet was
washed with 1.5 ml of methanol and vacuum-dried. Pro-
teins were then resuspended in 400 μl of 2-DE buffer (Cel-
lular and Organelle Membrane Solubilizing Reagent,
Sigma), reduced for 1 h at room temperature by adding
tributylphosphine to a final concentration of 5 mM, and
alkylated in the dark for 1.5 h at room temperature by
adding iodoacetamide to a final concentration of 15 mM.
Protein concentration was determined by using the Brad-
ford assay (Biorad).
Two-dimensional gel electrophoresis
The reduced and alkylated protein samples (300 μg) were
used to rehydrate 13 cm pH 3–10 NL Immobilized pH
Gradient (IPG) strips (Amersham Biosciences). 1.2 μl of
IPG buffer pH 3–10 NL (Amersham Biosciences) and 2 μl
of 1% (w:v) orange G were added to 250 μl of sample
before application to the strip. Strips were focused on the
IPGphor IEF (isoelectrofocusing) Cell (Amersham Bio-
sciences) for 80000 Vh. After 6 h of passive rehydration
and 6 h of active rehydration (30 V), the voltage was set to
300 V for 4 h. It was then increased from 300 to 8000 V
during 8 h, followed by additional hours at 8000 V (until
the desired volt × hour product is reached). Focused IPG
strips were equilibrated in SDS-equilibration buffer con-
taining 6 M urea, 2% (w:v) SDS, 50 mM Tris-HCl (pH
8.8), 30% (v:v) glycerol and 0.01% (w/v) bromophenol
blue as a tracking dye for 2 × 10 min. The equilibrated
strips were loaded onto 16 × 16 cm, 1 mm thick, 12%
Table 3: Proteins whose abundance in SH-SY5Y cells is regulated after 72 h of morphine treatment
Spot # Protein Accession # (a) MW (Da) Variation (% of 
control) (b)
MALDI peptides % coverage MS/MS peptides 
(c)
4 Radixin P35241 68564 50 ± 17 4
6 no identification 48 ± 23
8 Heat shock cognate 71 kDa protein P11142 70898 172 ± 48 11 23
10 Lamin A/C P02545 74139 78 ± 15 22 30
12 T-complex protein 1, zeta subunit P40227 57893 57 ± 17 15 29
13 Dihydropyrimidinase-related Q14195 61963 57 ± 21 13 40
protein 3
17 Septin-11 Q9NVA2 49267 110 ± 3 13 37
23 Rab GDP dissociation inhibitor beta P50395 50663 179 ± 61 11 34
24 Rab GDP dissociation inhibitor beta
Mitochondrial-processing peptidase 
beta subunit
P50395
O75439
50663
55072
114 ± 6 14
12
36
25
25 Proliferation-associated protein 2G4 Q9UQ80 43787 54 ± 20 15 44
26 Elongation factor 1-gamma P26641 49988 89 ± 5 16 36
28 Adenylosuccinate synthetase 2 P30520 50097 73 ± 16 5
29 Elongation factor 1-gamma
tRNA-nucleotidyltransferase 1
P26641
Q96Q11
49988
50340
51 ± 27 11
9
24
19
31 Ornithine aminotransferase. P04181 48535 84 ± 3 14 37
34 Septin-2 Q15019 41487 72 ± 15 12 36
39 Ubiquitin-like 1 activating enzyme 
E1A
Q9UBE0 38450 45 ± 14 11 35
40 Guanine nucleotide binding protein, 
alpha inhibiting activity polypeptide 2
Q96C71 40493 65 ± 8 9 37
43 3-mercaptopyruvate 
sulfurtransferase
P25325 33047 69 ± 9 6
44 Malate dehydrogenase, cytoplasmic P40925 36295 73 ± 16 11 32
45 Alpha-soluble NSF attachment 
protein
P54920 33247 45 ± 12 8 45
47 Nuclear protein Hcc-1 P82979 23540 77 ± 9 9 41
48 no identification 49 ± 32
49 Guanine nucleotide binding protein 
beta subunit 2-like 1
P63244 35077 74 ± 9 15 69
50 Proteasome subunit alpha type 3 P25788 28302 73 ± 13 8 46
55 Proteasome subunit beta type 6 P28072 25358 143 ± 11 7 23
aSwiss-Prot primary accession number
bMean ± S.D., control refers to untreated cells.
cOnly peptides with a statistically significant Mascot score (p < 0.05) were consideredProteome Science 2006, 4:23 http://www.proteomesci.com/content/4/1/23
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polyacrylamide SDS gels. Runs were performed at 10 mA/
gel (SE600 Ruby, Amersham Biosciences) until the
bromophenol blue reached the bottom of the gel. Gels
were then stained overnight using Coomassie colloidal
blue (1 g/l, Sigma) and destained for 1 h in 1% (v/v) acetic
acid solution.
Image analysis
Gels were scanned using a GS-800 Calibrated Densitome-
ter (Biorad) and analyzed using ImageMaster Platinum
software (Amersham Biosciences). Spots were detected on
quadruplicate gels and manually edited. Normalization
was performed by dividing the volume (OD × surface) of
each spot by the total volume of every spot on the gel to
give a %volume value. Gels were then matched and each
group of equivalent spots was compared. In a preliminary
experiment, 4 independent control gel were compared.
Pair-wise comparison of spot %volumes gave linear
regressions of the type y = ax + b where a = 1.03 ± 0.06 and
b = -0.0019 ± 0.0034, and a correlation coefficient of 0.95
± 0.011. Average coefficient of variation (SD/mean × 100)
for all spot %volumes was 19.8 ± 10.1. This level of repro-
ducibility is indicative of a statistical power of 80 to 90%
for a sample size of 4 and a 0.05 p-value [30]. Having
assessed the reliability of our analyses, %volumes of spots
from control gels were compared to those of spots from
treated gels using a Student unpaired t test. Groups of
spots showing a statistically significant difference in rela-
tive volume (p < 0.05, df = 6) between control and mor-
phine-treated samples were first visually controlled in
order to make sure that %volume changes were not due to
spot detection or matching errors. Confirmed spots were
then selected for identification by mass spectrometry.
In-gel protein digestion
Spots of interest were manually excised from a represent-
ative gel. The gel pieces were washed with water and
destained first in 160 μl of 50% (v:v) acetronitrile (ACN)
in water then in 160 μl of 50% (v:v) ACN in 0.1 M
NH4HCO3, dehydrated with 80 μl ACN and dried in a vac-
uum centrifuge. Gel pieces were rehydrated in a sufficient
covering volume of modified trypsin solution (12.5 ng/μl
in 12.5 mM NH4HCO3; Promega) and incubated over-
night at 37°C. Prior to peptide extraction, 0.5 μl of the
tryptic digest was spotted onto the MALDI target plate.
Peptides were extracted two times at 37°C for 30 min with
shaking, first using 50% 25 mM NH4HCO3 /50% ACN
and then 5% formic acid/50% ACN in water. The peptide
mixture was concentrated in a vacuum centrifuge to a final
volume of about 10 μl.
MALDI-TOF MS analysis
MALDI-TOF MS analyses were performed on a MALDI-
TOF/TOF instrument (4700 Proteomics Analyzer; Applied
Biosystems, Foster City, CA). 0.5 μl of tryptic digest super-
natant was loaded onto the MALDI target plate and air
dried. 0.3 μl of matrix solution (α-cyano-4-hydroxycin-
namic acid; 5 mg/ml in H2O/acetonitrile/TFA, 50:50:0.1)
was then added. Mass spectra were acquired in an auto-
mated positive reflector mode from m/z 700 to m/z 3500.
Trypsin autolytic peptides (m/z 842.51 and 2211.10) were
used to internally calibrate each spectrum to a mass accu-
racy within 30 ppm. Spectra were analyzed using GPS
Explorer (version 3.5, Applied Biosystems) which acts as
an interface between the Oracle database containing raw
spectra and a local copy of the Mascot search engine (ver-
sion 2.0 ; Matrix Science, London, U.K.). Peptide peaks
with a signal/noise ratio greater than 10 were searched
against human sequences in the Swiss-Prot database
(Release 48 from September 2005 ; 194 317 entries). No
missed cleavage was allowed and the data were searched
using carbamidomethylation of cysteine as fixed modifi-
cation whereas oxidation of methionine and N-acetyla-
tion of the proteins were considered as variable
modifications. A protein was considered correctly identi-
fied if the Protein Score Confidence Interval calculated by
the GPS Explorer Results Browser was greater than 99%
(see Additional file 2).
NanoLC-ESI-Q-TOF MS/MS analysis
When MALDI-TOF data were not conclusive (protein
score not significant), protein identification was con-
firmed by MS/MS analyses. Tryptic peptide extracts were
subjected to nanoLC-MS/MS analysis on an ESI-Q-TOF
mass spectrometer (QSTAR XL, Applied Biosystems) oper-
ating in positive mode with a 2.1 kV spray voltage. Chro-
matographic separation was performed onto a 75 μm ID
× 15 cm PepMap C18 column (Dionex/LC Packings, USA)
at a flow rate of 200 nL/minute using a linear gradient of
increasing ACN in water (5–50%) over 40 min with 0.1%
formic acid as ion pairing agent. Data were acquired with
Analyst QS (version 1.1, Applied Biosystems). MS spectra
were acquired for one second. For each MS spectrum, the
two most intense multiple charged peaks were selected for
generation of subsequent Collision Induced Dissociation
(CID) mass spectra. The collision energy was automati-
cally adjusted based upon peptide charge and mass to
charge (m/z) ratio. A dynamic exclusion window was
applied to prevent repetitive selection of the same ions
within 30 sec. Data were analyzed using Analyst QS soft-
ware (version 1.1) and MS/MS centroid peak lists were
generated using the Mascot.dll script (version 1.6b13).
MS/MS centroid peaks were thresholded at 0% of the base
peak. Data were searched against human sequences in the
Swiss-Prot/TrEMBL database as of October 2005 using
Mascot (version 2.0). Peptide tolerance in MS and MS/MS
modes was 0.5 Da. Trypsin was designated as the protease,
and up to two missed cleavages were allowed. Carbamid-
omethylation of cysteine was searched as fixed modifica-
tion, while oxidation of methionine and amino-terminalProteome Science 2006, 4:23 http://www.proteomesci.com/content/4/1/23
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protein acetylation were allowed as variable modifica-
tions. Identification was considered positive if the protein
was identified on the bases of at least two peptides with a
score greater then the significance threshold score deter-
mined by the Mascot Search program (>36) (see Addi-
tional file 2).
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